PolyActiva awarded $1.5m CUREator Grant
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily…
PolyActiva reports promising Phase 2a clinical trial results
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients. The interim Phase 2a results demonstrate a sustained >20% reduction of IOP…
PolyActiva presents positive clinical trial results
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022
Positive Phase IIa results in glaucoma trial with low dose cohort
PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.